Regulatory support for lead gene therapy candidates as a treatment for organic acidemias, propionic acidemia (PA) and methylmalonic acidemia type B (MMAB)
Ended Awarded Last action
- Contract number
- 75N95022F00001
- Awardee
-
MPF Federal, LLC UEI LLA5KJMFQPU8
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $179,041
Award facts
- Contract value 15% obligated
-
- $179,041.39 Current, with exercised options
- $1,189,645.80 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Labor Hours
- Place of performance
- Philadelphia, PA 19102, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $46,977 | |
| Exercise an Option | $9,626 | |
| Original award | $122,439 |
About this award
This is a federal contract awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to MPF Federal, LLC, a certified HUBZone, Woman-Owned, Minority-Owned Small Disadvantaged Business. The $1,189,645.80 contract provides regulatory support for the development of lead gene therapy candidates to treat two rare genetic disorders, propionic acidemia and methylmalonic acidemia type B. The contract has a performance period that ends on September 21, 2025. MPF Federal has an existing $19 million Indefinite Delivery, Indefinite Quantity (IDIQ) contract with the National Center for Advancing Translational Sciences to provide regulatory support services. This contract award does not utilize any small business set-aside program.
Quick answers
Who was awarded contract 75N95022F00001?
75N95022F00001 was awarded to MPF Federal, LLC by National Institute on Drug Abuse (National Institutes of Health) on September 22, 2022.
How much is contract 75N95022F00001 worth?
The government has obligated $179,041 on 75N95022F00001. Its potential value, with all options, is $1,189,646.
Which agency awarded contract 75N95022F00001?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022F00001, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95022F00001 an order under another contract?
Yes. 75N95022F00001 is a delivery order under 75N95022D00014, an indefinite delivery contract.
Was contract 75N95022F00001 competed?
The extent of competition for 75N95022F00001 was full and open competition after exclusion of sources. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award